Business
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024.
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis","length":111,"tagName":"p","attribs":{}},{"type":"text","content":"Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 trial design for ongoing KYSA-8 trial in stiff person syndrome; 70% of study enrolled with topline data expected in 1H 2026; Biologics License Application (BLA) filing targeted for 2026 ","length":276,"tagName":"p","attribs":{}},{"type":"text","content":"Clinical data in myasthenia gravis and lupus nephritis expected in 2H 2025 ","length":74,"tagName":"p","attribs":{}},{"type":"text","content":"Strong balance sheet extends cash runway into 2027 through key clinical and regulatory catalysts ","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"EMERYVILLE, Calif., March 27, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the full year 2024.","length":297,"tagName":"p"},{"type":"image","alt":"Kyverna Therapeutics logo (PRNewsfoto/Kyverna Therapeutics)","displaySize":"","headline":null,"caption":"Kyverna Therapeutics logo (PRNewsfoto/Kyverna Therapeutics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":109,"url":"https://media.zenfs.com/en/prnewswire.com/47b1067bc1996972874b5bd0b6458e9c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DA7ANgBTGxnuP.e80RfQ2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/47b1067bc1996972874b5bd0b6458e9c","width":400,"height":109}},"href":"https://mma.prnewswire.com/media/2595719/Kyverna_Therapeutics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Kyverna's first year as a public company was a transformative one, as we demonstrated our leadership position in autoimmune CAR T. We have treated the most CAR T patients in neuroinflammatory and rheumatologic diseases with our differentiated construct, and our clinical experience to date highlights the potential for profound clinical outcomes in autoimmune patients," said Warner Biddle, Chief Executive Officer of Kyverna. "Kyv...